NMPA (China) approves Mindewei ,formerly VV 116, to treat mild to moderate COVID- 19
The board of directors of Shanghai Junishi Biosciences is pleased to announce that on 28 January 2023, pursuant to relevant regulations of the Drug Administration Law, the National Medical Products Administration (the NMPA) conducted urgent review and approval under Special Examination and Approval of Drugs and conditionally approved deuremidevir hydrobromide tablets (trade name: Mindewei, product code: VV116/JT001, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 Category 1 innovative drug for marketing, which was applied by Shanghai Vinnerna Biosciences Co., Ltd a subsidiary controlled by the Company, for the treatment of adult patients with mild to moderate coronavirus disease 2019
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins